the authors report the clinical results and the cost/benefit analysis of a protocol of passive prophylaxis of hepatitis b based on the administration of two doses of three ml each of hbig and on the control of anti-hbs levels by ria for six months after accidental exposure in health-care personnel .
C0019163
a
C0062525
hbig